Madigan Catherine has filed 3 insider transactions across 2 companies since February 2023.
Most recent transaction: a grant/award of 145134 shares of Hemab Therapeutics Holdings, Inc. ($COAG) on January 29, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 29, 2026 | Hemab Therapeutics Holdings, Inc. | $COAG | Madigan Catherine | Chief Medical Officer | A | Warrants (Right to Buy) | 145134 | $0.00 | 145,134.0000 | 0 | 9999.99% | 0.00% |
| April 30, 2026 | Hemab Therapeutics Holdings, Inc. | $COAG | Madigan Catherine | Chief Medical Officer | A | Stock Option (Right to Buy) | 49016 | $0.00 | 49,016.0000 | 0 | 9999.99% | 0.00% |
| Feb. 2, 2023 | Syndax Pharmaceuticals Inc | $SNDX | Madigan Catherine | Chief Medical Officer | A | Stock Options (Right to buy) | 110000 | $28.55 | 110,000.0000 | 0 | 9999.99% | 0.00% |